SUMMARY In 65 patients with primary invasive ductal breast carcinoma the relation between classic prognosticators describing the extent of disease (lymph node metastases and tumour size) and newer promising morphometric and DNA flow cytometric prognostic factors was studied. There was no relation between DNA ploidy, lymph node state, and tumour size. Tumours with a mitotic activity index of more than 10 were predominantly DNA aneuploid (61%) compared with those with a mitotic activity index of less than 10 which showed a DNA aneuploid pattern in 27%. The strongest prognosticator, the morphometric prognostic index (a multivariate combination of mitotic activity index, tumour size, and lymph node state) correlated positively with the DNA index in 63% of the cases (p = 0-038). Thus there was a discrepancy between the morphometric and DNA flow cytometric prognostic variables in 37% of the cases. These results indicate that morphometric and flow cytometric analysis may provide additional information on the prognosis in primary breast cancer.
The mortality of breast cancer is 30 per 100000 women per year in western Europe; the incidence is about 65 per year and still increasing. In spite of many developments in surgery, hormone treatment, and (adjuvant) chemotherapy, prognosis has only slightly improved over the past few decades. ' 2 Some patients, however, do benefit from adjuvant therapy.3 Indeed, patients with metastases in their lymph nodes have a much less favourable prognosis than patients with no lymph node disease, although the sensitivity and specificity of lymph node state is not very high, 24 which results in an imbalance of treatment. Additional or other prognostic factors, which can help select specific treatments are obviously needed.
Pathologists have developed several grading systems relating to survival over many decades.' 6 In spite of its well documented prognostic value, nuclear or histological grading for breast cancer is used much less extensively in therapeutic decision making than clinical staging, principally because grading is not objective and reproducibility is therefore poor.7 8 Furthermore, it is difficult to predict the outcome in an individual patient if the grade of tumour falls within the relatively large "grey zone" (moderately Accepted for publication 26 March 1987 differentiated or grade II). Consequently, the value of grading in an individual patient is restricted, and as a result, a correct prediction of prognosis can be achieved in only 60% of patients.8
Many attempts have been made to identify more accurately patients at high risk. Women with tumours in which steroid receptors are demonstrable have a better survival than women with tumours in which such receptors are lacking.9 Unfortunately, recent data indicate that this is only true in the short term, thus reducing the predictive prognostic value of these receptors. 10 1 1 Much work has therefore been done during the past few years to develop several objective prognostic variables.2 -15 Morphometric variables like cellularity index, nuclear area and shape, ratio of longest and shortest axis in primary and secondary tumours, the mitotic activity index (MAI) and the morphometric prognostic index (MPI) have been shown to be accurate prognostic indicators in breast cancer. 13 -15 Moreover, cellular DNA content can be measured on human solid tumours, and according to the findings of many reports, offers additional objective information for prediction of prognosis. 12 -017654 (lymph node state) (negative = 2, positive = 1) The reproducibility of the morphometric assessments was tested in 10 random samples (intraobserver and interobserver, table 2). Coefficients of correlation (r) within and between operators in 10 specimens ranged from 0 93 to 0-98 for the mean area, respectively, and 0-98 for both tests in the MAI. The measurementswere therefore sufficiently reproducible.
FLOW CYTOMETRY
All samples were analysed within three hours after DAPI staining on a Partec flow cytometer (Partec Instruments, Arlesheim, Switzerland). The coefficient of variation (CV) of the G1 peak in all the measured samples was between 1-8% and 6%. We defined the CV as the ratio of the half width at 61% ( x 2 standard deviations) of Go/G1 and the value of the GO/GI peak on the abscissa. Formalin fixed mouse thymocytes served as an external standard for instrument setting (optimal CV = 1[5%, with a mean value of 2 1%). Reproducibility of measurements between different blocks of the same tumour as well as between intra-and interobserver measurements were tested in 10 random samples (table 2). No significant Uyterlinde, Schipper, Baak differences were noted (r = 0-98). The DNA index was determined from the histograms: this is the ratio of the second Go/Gl to the first GO/GI peak in the DNA histogram. In agreement with others, we made the assumption that the first GO/GI peak represented diploid cells, either from the tumour or other cells present (inflammatory cells or fibroblasts).222" A diploid (DNA index = 1.0) tumour showed only one Go/G1 peak in the expected region (= 2c) in the histogram. An aneuploid tumour (DNA index> 1-0) showed an additional peak to the 2c peak. Multiploid tumours showed at least three different GO/GI peaks.
STATISTICAL ANALYSIS
Statistical analysis was carried out using the BMDP package. The difference between means was evaluated by Student's t test. The DNA index could not be regarded as a normal continuous distribution because of the over-representation of diploid tumours and was therefore divided into diploid (DNA index = I -0) or aneuploid (DNA index of >I 0). Similarly, the MPI was divided into two groups using the previously established cut off point of 0 60. 5 22 In these studies this cut off point was chosen for comparison with lymph node state so that the number of patients in the low index group was the same as the number of patients with unaffected lymph nodes. Similarly, the number of patients in the high index group equalled the number of patients with affected lymph nodes.
Values of p < 0-05 (X2 test) were regarded as significant.
Results
Fifty four percent of patients showed a high MAI (> 10) with an average of 13-7 (SD 1.4). Using the cut off value of 0-60, 54% showed an MPI of < 0.60 (low risk) and 46% of > 0 60 (high risk). Measurements of DNA fluorescence showed a diploid tumour pattern in 52%; 48% had an aneuploid tumour peak (table 3) . Eighteen (27%) patients with an aneuploid tumour showed a DNA index between 1-50 and 2-0. Two tumours showed an additional aneuploid peak in the DNA index region of 1-55 and 2-1. Only three tumours were tetraploid.
To establish therapeutic relevance the tumour sizes of the 65 tumours were divided into t under 2cm, over 3 cm, and in between. no correlation between ploidy and these tumour size could be found (table 1) . Di cellular DNA content in relation to lym] is also shown. In agreement with others, no significant correlation. Table 1 gives an impression of the dis the nuclear areas of diploid and aneupl In general, DNA aneuploid tumours I nuclear area (65-60 (SD 23.6) gtm comf nuclear area of 56 95 (SD 18.0) gsm tumours. This difference is just below significance (t test = -164, p = 0I 1).
There was a significant correlation b and DNA index (tables 1 and 4) . Dip] showed a low MAI and aneuploid tumoi In conclusion, the combination of the MPI and the DNA index is a promising predictor of prognosis in primary ductal breast cancer. Further evaluation of these tumour characteristics in relation to survival and length of remission is needed. A study on this subject has already been started.
